Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena initiates Phase II atherosclerosis trial
The initiation of this trial does not trigger a milestone payment. The Phase II clinical trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, as well
The initiation of this trial does not trigger a milestone payment. The Phase II clinical trial is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, as well
The series B funding will be used by the company to complete a Phase I study investigating a novel topical treatment for acne, preclinical studies on a nebulized
United BioSource Corporation (UBC) will continue to support customers from its multiple operations located throughout the US, Europe and Japan, providing a full suite of specialty clinical services
Orexo will supply Neopharm with Abstral product in Israel and receive significant margin on the sales of the product. The agreement also includes milestone payments; however the financial
All existing investors participated, including Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, BBT Capital Management/Apothecary Capital, Jafco, PFM, and Altitude Life Science Ventures. The company plans to
China-Biotics, a manufacturer of probiotics products, has reported a net income of $5.67m, or $0.22 per diluted share, for the third quarter ended December 31, 2008, compared to
Net income for the year ended December 31, 2008 was $11.1 million, or $0.87 per fully diluted share, compared to $8.4 million, or $0.72 per diluted share, for
Net income for the year ended December 31, 2008 was $30.8 million, or $0.29 per fully diluted share, compared to a net loss of $15.8 million, or $0.16
For the full year 2008, the company posted net revenues of CHF1.47 billion, an increase of 12%, compared to CHF1.32 billion for the full year 2007. Jean-Paul Clozel,
Diamyd Medical, a biopharmaceutical company, has received approval from the Swedish Medical Products Agency to continue to follow the children who participated in the company’s Phase II study